Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 31, Number 2—February 2025
Dispatch
Outbreak of Serotype 1 Invasive Pneumococcal Disease, Kibera Urban Informal Settlement, Nairobi, Kenya, 2023
, Patrick K. Munywoki, Maria da Gloria Carvalho, Joshua Auko, Alice Ouma, Allan Audi, George O. Agogo, Daniel Omondi, Arthur Odoyo, Herine Odiembo, Newton Wamola, Mike Osita, Clayton Onyango, Naomi Lucchi, Peninah Munyua, Amy Herman-Roloff, Shanda Larson, Sopio Chochua, Fabiana C. Pimenta, Godfrey Bigogo, and Jennifer R. Verani
Table 2
Enrollment of SARI cases, pneumococcal carriage testing, and serotyping, Kibera Urban Informal Settlement, Nairobi, Kenya, January 1, 2018–August 20, 2024*
| Year | SARI cases | NPs collected and tested | Poor growth† | Pneumococcus isolated‡ | Serotyped | ST1 | Other PCV10 types§ | Non-PCV10 types | Serotype pending |
|---|---|---|---|---|---|---|---|---|---|
| 2018 | 264 | 233 (88.3) | 4 (1.7) | 161/229 (70.3) | 161 (100) | 2 (1.2) | 43 (26.7) | 115 (71.4) | 0 |
| 2019 | 318 | 312 (98.1) | 0 | 174/312 (55.8) | 174 (100) | 4 (2.3) | 33 (19.0) | 137 (78.7) | 0 |
| 2020 | 78 | 73 (93.6) | 1 (1.4) | 32/72 (44.4) | 32 (100) | 1 (3.1) | 1 (3.1) | 25 (78.1) | 0 |
| 2021 | 133 | 110 (82.7) | 11 (10.0) | 40/99 (40.4) | 39 (97.5) | 0 | 7 (18.0) | 31 (79.5) | 1 (2.5) |
| 2022 | 113 | 106 (93.8) | 4 (3.8) | 59/102 (57.8) | 58 (98.3) | 0 | 18 (31.0) | 36 (62.1) | 1 (1.7) |
| 2023 | 125 | 120 (96.0) | 11 (9.2) | 58/109 (53.2) | 56 (96.6) | 10 (17.9) | 13 (23.2) | 21 (37.5) | 2 (3.4) |
| 2024 | 222 | 190 (85.6) | 14 (7.4) | 78/176 (44.3) | 74 (94.9) | 1 (1.4) | 9 (12.2) | 60 (81.1) | 4 (5.1) |
*Values are no. (row %) except as indicated. NP, nasopharyngeal swab sample; PCV10, 10-valent pneumococcal conjugate vaccine; PCV10-GSK, Synflorix 10-valent PCV (GlaxoSmithKline, https://www.gsk.com); PCV10-SII, (Pneumosil 10-valent PCV (Serum Institute of India, https://www.seruminstitute.com); SARI, severe acute respiratory illness; ST1, serotype 1. †Poor growth defined as<10 colonies of any bacteria. ‡Excludes samples with poor growth. §Includes serotypes common to PCV10-GSK and PCV10-SII (5, 6B, 7F, 9V, 15, 19F, and 23F), PCV10-GSK unique (4 and18C), and PCV10-SII unique (6A and 19A).